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Abstract The natriuretic peptides, Atrial-, B-type and C-type
natriuretric peptides (ANP, BNP, CNP), are regulators of many
endocrine tissues and exert their effects predominantly through
the activation of their specific guanylyl cyclase receptors (GC-A
and GC-B) to generate cGMP.Whereas cGMP-independent sig-
nalling has been reported in response to natriuretic peptides, this
is mediated via either the clearance receptor (Npr-C) or a renal-
specific NPR-Bi isoform, which both lack intrinsic guanylyl cy-
clase activity. Here, we report evidence of GC-B-dependent
cGMP-independent signalling in pituitary GH3 cells.
Stimulation of GH3 cells with CNP resulted in a rapid and
sustained enhancement of ERK1/2 phosphorylation (P-ERK1/
2), an effect that was not mimicked by dibutryl-cGMP.
Furthermore, CNP-stimulated P-ERK1/2 occurred at concentra-
tions below that required for cGMP accumulation. The effect of
CNP on P-ERK1/2was sensitive to pharmacological blockade of
MEK (U0126) and Src kinases (PP2). Silencing of the GC-B1
and GC-B2 splice variants of the GC-B receptor by using
targeted short interfering RNAs completely blocked the CNP
effects on P-ERK1/2. CNP failed to alter GH3 cell proliferation
or cell cycle distribution but caused a concentration-dependent
increase in the activity of the human glycoprotein α-subunit
promoter (αGSU) in a MEK-dependent manner. Finally, CNP
also activated the p38 and JNK MAPK pathways in GH3 cells.
These findings reveal an additional mechanism of GC-B signal-
ling and suggest additional biological roles for CNP in its target
tissues.
Keywords Natriuretic . cGMP .Guanylyl cyclase . Pituitary .
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Introduction
Themammalian family of particulate guanylyl cyclases currently
comprises six identified members (GC-A to -F) that act as recep-
tors for the natriuretic peptides, heat-stable enterotoxins and
odour molecules and as phototransducers (Potter et al. 2006;
Garbers et al. 2006). These receptors and their orthologues me-
diate a diverse range of functions across many species. The na-
triuretic peptides, Atrial-, B-type and C-type natriuretic peptides
(ANP, BNP and CNP, respectively), exert the vast majority of
their effects via either the GC-A (Npr1, ANP-specific) or GC-B
(Npr2, CNP-specific) receptors (Potter et al. 2006; Garbers et al.
2006) by mechanisms that involve the intrinsic guanylyl cyclase
activity of these receptors, leading directly to cGMP generation.
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Although some non-cGMP-mediated effects of natriuretic pep-
tides have been reported, these are thought to bemediated via the
non-guanylyl cyclase, NPR-C (Npr3) receptor (also referred to as
the clearance receptor; Anand-Srivastava 2005). Investigation of
GC-B knock-outmice has suggested roles for GC-B signalling in
bone development, female reproductive function and pituitary
growth hormone expression (Chusho et al. 2001; Tamura et al.
2004). However, in many GC-B-expressing tissues, the regula-
tion of local cGMP concentrations remains the only biological
function identified to date (Fowkes and McArdle 2000).
The anterior pituitary gland expresses high tissue concentra-
tions of the GC-B ligand, CNP, plus all three natriuretic peptide
receptors (Fowkes and McArdle 2000; Komatsu et al. 1991;
Grandclément et al. 1995). Our previous studies revealed that
CNP potently stimulates cGMP accumulation in rodent pituitary
cell lines and primary rat pituitary cultures (Fowkes et al. 2000;
Shimekake et al. 1994; Thompson et al. 2009, 2014) and some
studies have indicated a function for GC-B and cGMP in medi-
ating pituitary growth hormone secretion (Shimekake et al. 1994;
Hartt et al. 1995). Furthermore, we have demonstrated the ex-
pression of CNP and GC-B in fetal, normal adult and adenoma-
tous human pituitary tissue, including those from acromegalic
patients (Thompson et al. 2012). However, the effects of CNP
on somatotrope proliferation and associated signalling pathways
have not been established.
Several groups have investigated the potent anti-proliferative
effects of the natriuretic peptides and CNP, in particular, by
mechanisms involving the GC-B/cGMP/protein kinase G
(PKG) inhibition of the mitogen-activated protein kinase
(MAPK) pathway (Hagiwara et al. 1996; Kaneki et al. 2008).
Recently, a combination of CNP and the phosphodiesterase 5a
inhibitor, Sildenafil, has been shown to inhibit MAPK signalling
and cell proliferation of rhabdomyosarcoma cells (Zenitani et al.
2016). Interestingly, this same combination of treatments poten-
tiates the growth of melanoma cells in a cGMP/PKG/MAPK-
dependent manner (Dhayade et al. 2016). In our current study,
we seek to investigate the potential role of CNP in pituitary
MAPK signalling. We demonstrate that CNP potently stimulates
the phosphorylation of extracellular regulated kinase 1/2
(ERK1/2) in pituitary GH3 somatolactotrope cells at concentra-
tions at which cGMP levels are not affected. These effects appear
to be cGMP-independent but GC-B–dependent, as determined
by silencing of the GC-B receptor, indicating an alternative
mechanism by which members of the particulate guanylyl cy-
clase family may signal.
Materials and methods
Cell culture and treatments
GH3, αT3–1 and LβT2 cells were grown and main-
tained in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma, Poole, UK) containing penicillin/
s t reptomycin and 10% feta l ca l f serum (FCS;
Invitrogen, Paisley, UK) at 37 °C, 5% (v/v) CO2 in
air as previously described (Thompson et al. 2012,
2014). Cells were plated at a density of 1 × 106 cells/
well for Western blotting and RNA extraction and at
3 × 105 cells/well for reporter gene assays and cGMP
determinations. CNP, ANP, forskolin, db-cGMP,
BAPTA-AM, GF109203X, genistein, H89, herbimycin
A, nifedipine, protein phosphatase 2 (PP2), PP3, PI3K
(phosphatidyl inositol 3-kinase) inhibitor (LY294006)
and U0126 were obtained from Calbiochem (Merck
Chemicals, UK) or Sigma (Sigma-Aldrich, Poole, UK).
All compounds, except for nifedipine, were stored
aliquoted as stock solutions at -20 °C.
Immunoblotting
Cells were serum-starved overnight prior to drug treatment.
Following stimulation, cell lysates were harvested in lysis
buffer (0.5 M TRIS pH 6.8, 10% (v/v) glycerol, 1% (w/v)
SDS) containing phosphatase inhibitor cocktails 1 and 2
(Sigma, Dorset, UK). Protein lysates were sonicated, boiled
at 95 °C for 5 min, resolved by using 10% SDS-
polyacrylamide gel electrophoresis, transferred to
polyvinylidene difluoride membrane and probed with the fol-
lowing: primary antibodies against P-P-ERK1/2, total
ERK1/2, P-p90RSK, P-Elk-1, P-CREB, CREB, P-p38, total
p38, P-JNK, total JNK (all from Cell Signalling, NEB,
Hitchin, UK), GC-B (Santa Cruz, Calif., USA) and β-Actin
(Abcam, Cambridge, UK). Appropriate horseradish peroxi-
dase (HRP)-conjugated secondary antibodies were purchased
from DAKO (Cambridge, UK). In some instances, scanning
densitometric analysis was carried out by using a BioRad
scanner and the Quantity One scanning densitometry software
package (Bio-Rad Hertfordshire, UK). The density of the P-
ERK1/2 and total ERK1/2 bands in each lane was quantified
and the ratio of P-ERK1/2 to the corresponding total ERK1/2
lane was calculated.
cGMP and cAMP enzyme immunoassay
Cell treatments were conducted in physiological saline solu-
tion (PSS: 127 mM NaCl, 1.8 mM CaCl2, 5 mM KCl, 2 mM
MgCl2, 0.5 nM NaH2PO4, 5 mM NaHCO3, 10 mM glucose,
10 mMHEPES pH 7.4, 0.1% [w/v] bovine serum albumin) in
the presence of 1 mM 3-isobutyl-1-methylxanthine (IBMX),
as described previously (Thompson et al. 2012). Cell stimula-
tions were terminated by addition of ice-cold absolute ethanol
and cGMP or cAMP concentrations determined as instructed
by the manufacturer (R&D Systems, Abingdon, UK).
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Transfections and RNA interference
For transfections, 3 × 105 GH3 cells/well were plated in 24-
well plates and transfected by using Lipofectin (Invitrogen)
with 1.25 μg/well -517αLUC together with 0.5 μg/well
BosβGal. Total protein extracts were assayed for reporter
gene activity as described previously (Thompson et al.
2009). For RNA interference, pre-designed GC-B short inter-
fering RNA (siRNA) or scrambled RNA control (Ambion
Biosciences, Invitrogen) were introduced into GH3 cells by
the lipofectin siRNAmax reverse-transfection method
(Invitrogen). For MAPK phosphatase-1 (MKP1) over-
expression studies, 5 μg/well MKP1 or pcDNA expression
vectors were reverse-transfected into GH3 cells, prior to se-
rum starvation and subsequent stimulation.
Reverse transcription and polymerase chain reaction
For reverse transcription (RT), total RNA was extracted by
using Tri-reagent (Sigma, Poole, UK) and subjected to
DNase treatment (Qiagen, Crawley, UK) before the genera-
tion of first-strand cDNA (Applied Biosystems, UK). The
polymerase chain reaction (PCR) was performed for a range
of targets over 30 cycles with the following primers: Npr1 (5′)
AAGCTTATCTGGAGGAGAAGCGCA and (3 ′ )
TCAGCCTCGAGTGCTACATCCCCG; Npr2 (5 ′ )
GGTACCAGCATATTGGACAACCTC and ( 3 ′ )
CAGGAGTCCAGGAGGTCTTTTTCG; GC-B1/2 (5′)
GAAGCTGATGCTGGAGAAGGAGC and ( 3 ′ )
GACAATACTCGGTGACAATGCAG; GC-B1/3 (5′)
ACGGGCGCATTGTGTATATCTGCGGC a n d
TTATCACAGGATGGGTCGTCCAAGTCA; Npr3 (5′)
CCCTCCAAACAGTCACCCTA and (3′) CCATCCTT
CTTGCTGTAGCC; Rpl19 (5′) CTGAAGGTCAAAGG
GAATGTG and (3′) GGACAGAGTCTTGATGATCTC.
Cell proliferation assays
For all assays, GH3 cells were plated into 6-well plates in
DMEM supplemented with 2% (v/v) FCS (control), 2%
(v/v) FCS containing 100 nM CNP, or 10% (v/v) FCS (posi-
tive control) and grown for 48 h before being harvested. For
cell counting, cells were harvested and cell numbers were
determined by 0.4% (w/v) trypan blue exclusion methodolo-
gy. For flow cytometry analysis, cells were harvested and re-
suspended in 500 μl phosphate-buffered saline containing
0.1% (w/v) glucose, before being fixed in 70% (v/v) ice-
cold ethanol, washed and re-suspended in a propidium iodide
solution (69 μM propidium iodide, 38 mM sodium citrate,
20 mg/ml RNase pH 7.4) and incubated for 40 min at 37 °C.
Cells were subjected to analysis by means of a Beckman
Coulter EPICS XL-MCL flow cytometer and Beckman
Coulter Expo 32 software, as described previously
(Thompson et al. 2009). For tritiated thymidine incorporation,
cells were incubated with 1 μCi/well tritiated thymidine for
the last 6 h of the 48 h incubation period, before being har-
vested with 0.5 M NaOH/0.5% sodium dodecyl sulphate
(SDS) and the addition of scintillation fluid. Samples were
counted by using a Packard 1500 TriCarb Scintillation
analyser with built-in software, as described previously
(Thompson et al. 2009). Metabolic activity assays (MTT as-
say) were performed by using the Promega CellTiter 96
Aqueous One assay according to the manufacturer’s instruc-
tions (Promega, Southampton, UK). Briefly, 20 μl/well
CellTiter 96 AQueous One Solution Reagent was added at
the end of the 48 h incubation, before measurement of the
absorbance at 490 nm on a Berthold Technologies Mithras
LB940 plate reader with MicroWin-4.40-associated software.
Data presentation and analyses
All experiments were performed a minimum of three times,
with autoradiographs being representative of these experi-
ments. For cGMP, cAMP, cell proliferation and luciferase ac-
tivities, the data shown are normalised and represent the
means ± SEM of at least three independent experiments, each
performed in triplicate. Numerical data were subjected to anal-
ysis of variance (ANOVA) and were followed, where appro-
priate, by Bonferroni’s multiple comparisons test, accepting
P < 0.05 as significant, with in-built equations in GraphPad
Prism 7.0a (GraphPad, San Diego, Calif., USA).
Results
CNP and ANP effects on ERK1/2 phosphorylation inGH3
somatolactotropes
Initial RT-PCR analyses were performed to determine the par-
ticulate guanylyl cyclases that were expressed in GH3 cells.
As shown (Fig. 1a), GH3 cells expressedNpr1 (encoding GC-
A) and all three splice variants of Npr2 (encoding GC-B).
Having established the presence of transcripts for both GC-
A and GC-B receptors in GH3 cells, we next investigated
whether these receptors were functional by measuring
cGMP accumulation. GH3 cells were stimulated with a range
of concentrations of CNP or ANP (from 10pM to 100 nM) in
PSS containing 1 mM IBMX to inhibit phosphodiesterase
activity. As shown (Fig. 1b, c), both CNP and ANP caused
an increase in the total concentration of cGMP, indicating the
presence of functional GC-B and GC-A receptors, as we and
others have described previously (Shimekake et al. 1994;
Fowkes et al. 2000; Thompson et al. 2014). To establish
whether CNP and ANP could stimulate P-ERK1/2, we stim-
ulated GH3 cells with the same concentration range of both
peptides for 15 min, prior to the extraction of total protein and
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Western blotting for phosphorylated ERK1/2 (P-ERK1/2).
Interestingly, not only did both peptides cause enhanced P-
ERK1/2 but they did so at concentrations below those needed
for cGMP accumulation, indicating that CNP and ANP can
activate the cGMP and the ERK1/2 pathways in GH3 cells,
albeit at differing efficacies. The similar nature of the P-
ERK1/2 response to CNP and ANP suggested the involve-
ment of a common receptor, such as the NPR-C clearance
receptor. However, RT-PCR analysis revealed that GH3 cells
failed to express transcripts for Npr3 encoding NPR-C
(Fig. 1d), in keeping with our previous studies (Thompson
et al. 2014). As the inhibition of cAMP production has previ-
ously been indicated as evidence of NPR-C activity (Sciarretta
et al. 2013), we examined the potential effect of CNP on
forskolin (FSK)-stimulated cAMP accumulation in GH3 cells.
As shown (Fig. 1d’), CNP failed to alter the FSK-stimulated
cAMP increase, suggesting a lack of functional NPR-C recep-
tors in these GH3 cells.
As previous studies have implicated CNP as the major
natriuretic peptide of the anterior pituitary (McArdle et al.
1993; Fowkes et al. 2000; Thompson et al. 2009, 2014), we
focused our subsequent experiments on the CNP/GC-B re-
sponse in GH3 cells. To characterise the ERK1/2 response to
CNP further, we examined the kinetics and localisation of P-
ERK1/2 in GH3 cells. GH3 cells treated with 100 nM CNP
showed a rapid enhancement in P-ERK1/2 within 5 min
(Fig. 2a); this was sustained for at least 30 min. To establish
whether the elevation of cGMP levels alone could mimic the
P-ERK1/2 response, a similar time-course experiment was
performed by using the cell permeable cGMP analogue,
dibutryl-cGMP (db-cGMP); as shown (Fig. 2b), 1 mM db-
cGMP failed to enhance P-ERK1/2 levels at any time point.
As the sub-cellular location of P-ERK1/2 can influence its
biological role, we used immunofluorescent microscopy to
Fig. 1 Natriuretic peptide effects on extracellular regulated kinase 1/2
(ERK1/2) phosphorylation and cGMP accumulation in GH3 cells. a
Reverse transcription plus polymerase chain reaction (RT-PCR) analyses
of GC-A (Npr1) and GC-B (Npr2) expression in GH3 cells. b, c
Concentration-response studies of ERK1/2 phosphorylation (P-ERK1/2)
or cGMP accumulation in response to (b) C-type natriuretric peptide
(CNP) or (c) Atrial-type natriuretric peptide (ANP). In both instances,
cells were stimulated for 15 min with the indicated concentrations of
CNP prior to extraction of total proteins for Western blotting or total
(intra- and extracellular) cGMP accumulation, as determined by cGMP
enzyme immunoassay. Each autoradiograph is representative of at least
three independent experiments; the scanning densitometry of ERK1/2
phosphorylation is pooled from at least three independent experiments.
The cGMP data are expressed as the percentage of response to 10−7 M
CNP or ANP for both ERK1/2 phosphorylation and cGMP accumulation.
d RT-PCR analysis of Npr3 expression in GH3 cells and mouse
gonadotrope αT3–1 and LβT2 cells (30 cycles). d’ GH3 cells were un-
treated (Basal) or treated with CNP (100 nM), forskolin (FSK, 10 μM) or
both CNP and FSK for 15 min prior to the determination of total (intra-
and extracellular) cAMP accumulation by cAMP enzyme immunoassay.
Data shown are means ± SEM from three independent determinations
Cell Tissue Res
examine the spatial properties of CNP-stimulated P-ERK1/2.
As shown (Fig. 2c–e), P-ERK1/2 was located in the nucleus of
GH3 cells following treatment with 100 nM CNP for 30 mins
and remained there for at least 60 min.
GC-B dependence of CNP-stimulated P-ERK1/2 in GH3
somatolactotropes
Having excluded a possible role for the NPR-C receptor in
mediating the CNP effects on P-ERK1/2, we next determined
whether these effects were mediated via the GC-B receptor.
Specific siRNA targeting of the GC-B receptor was performed
in GH3 cells; RT-PCR for GC-B expression revealed the si-
lencing of GC-B mRNA expression with the GC-B-specific
siRNA but not with the scrambled RNA controls (Fig. 3a).
Loss of GC-B protein in siRNA-treated GH3 cells was con-
firmed by Western blotting (Fig. 3b). Having confirmed the
successful silencing of GC-B expression, we performed func-
tional assays to determine the dependency of CNP-stimulated
P-ERK1/2 on GC-B receptors. As shown, GC-B-silenced
GH3 cells failed to respond to 100 nM CNP in terms of P-
ERK1/2 (Fig. 3c, left), although these responses remained
intact in scrambled RNA-treated GH3 cells (Fig. 3c, right).
As the GC-B-specific siRNA oligonucleotides were known
to target exons 21 and 22 in the Npr2 gene (present in both
GC-B1 and GC-B2 splice variants), we performed RT-PCR on
siRNA-treated GH3 cells. As shown (Fig. 3d), siRNA-treated
GH3 cells specifically lost the expression of GC-B1 and GC-
B2 transcripts but not the truncated GC-B3 expression.
Collectively, these data demonstrate the potential requirement
for both GC-B isoforms in mediating CNP effects on P-
ERK1/2 in GH3 somatolactotropes.
Mechanisms of CNP-stimulated P-ERK1/2 in GH3 cells
As cGMP alone failed to mimic the effects of CNP on P-
ERK1/2, we next examined putative signalling mechanisms
to explain these effects of CNP on the ERK1/2 pathway. GH3
cells pre-treated with the MAPK kinase 1/2 (MEK1/2) inhib-
itor (U0126; 1-30 μM for 30 min) exhibited blunted P-ERK1/
2 in response to CNP treatment (Fig. 4a, left). In similar stud-
ies, the Src-kinase-selective inhibitor (PP2; 1-30 μM for
30 min) concentration-dependently attenuated CNP-
stimulated P-ERK1/2 (Fig. 4a, right). Interestingly, other re-
ceptor tyrosine kinase inhibitors (genistein, herbimycin A,
PP3; 10 μM), all failed to affect CNP-stimulated P-ERK1/2
(Fig. 4b). As CNP can alter Ca2+ mobilisation, PI3K, protein
Fig. 2 Time-course analysis of CNP and dibutryl-cGMP (db-cGMP)
effects on ERK1/2 phosphorylation in GH3 cells. a, b GH3 cells were
stimulated with (a) CNP (100 nM) or (b) db-cGMP (8-Br-cGMP; 1 mM)
for up to 90 min, prior to extraction of total proteins andWestern blotting
for ERK1/2 phosphorylation. Each autoradiograph is representative of at
least three independent experiments. c–e’GH3 cells were treated for up to
90 min with 100 nM CNP prior to being fixed and stained for phospho-
ERK1/2 (Alexa-488, green) or nuclear co-stained (DAPI 4,6-diamidino-
2-phenylindole, blue). Immunofluorescence was visualised using confo-
cal microscopy. Images shown are a representative field of vision from at
least three independent experiments
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kinase A (PKA) and PKC activity in a range of cells (Fowkes
et al. 1999; Sun et al. 2006; Rose et al. 2007; Chen et al. 2014;
De Jonge et al. 2014), we examined the requirement for these
pathways in mediating the effects of CNP. GH3 cells pre-
treated (1-30 μM for 30 min or 15 min) with BAPTA-AM,
nifedipine, H89, GF109203X or PI3K inhibitor (LY294006),
all failed to alter CNP effects on P-ERK1/2 (Supplemental
Fig. 1). Having demonstrated the pharmacological blockade
of CNP-stimulated P-ERK1/2 with U0126, we used the over-
expression of the ERK1/2-associated phosphatase, MKP1, to
disrupt CNP signalling. As shown (Fig. 4c), GH3 cells tran-
siently transfected with 5 μg/well MKP-1 expression vector
expressed MKP1 protein more abundantly than cells
transfected with the empty pcDNA vector. The presence of
overexpressed MKP1 protein led to an attenuation in CNP-
stimulated P-ERK1/2 (Fig. 4c). Finally, in order to determine
whether CNP-stimulated cGMP accumulation was dependent
uponMEK activity, GH3 cells were pretreated for 30min with
Fig. 3 CNP stimulation of ERK1/2 phosphorylation is GC-B dependent.
a RT-PCR analyses showing the optimisation of GC-B silencing by using
short interfering RNA (siRNA). Total RNAwas prepared from GH3 cells
and reverse-transfected with the indicated concentrations of siRNA to
GC-B or scrambled RNA control (20 nM) and harvested at 48 h post-
transfection. bWestern blotting to determine loss of GC-B protein in GC-
B siRNA-treated GH3 cells (decreasing protein concentrations loaded per
well). Total proteins were extracted at 48 h post-transfection and cell
lysates were subjected to Western blot analyses for GC-B and then
stripped and re-probed for β-Actin. c Western blotting analyses of GC-
B siRNA-treated GH3 cells. GC-B siRNA or scrambled RNA-treated
GH3 cells were stimulated with the indicated concentrations of CNP for
15min. Cell lysates were subjected toWestern blot analyses for phospho-
ERK1/2 and then stripped and re-probed for total ERK1/2. d Specific
silencing of GC-B1 and GC-B2 splice variant expression by using GC-
B siRNA resulted in the loss of GC-B1 and GC-B2 (as determined by
primers targeting the exon 20 to 22 region) but not GC-B1 andGC-B3 (as
determined by primers targeting exon 5). In each case, the major band
represents GC-B1. Each autoradiograph is representative of at least three
independent experiments
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0 or 30 μM U0126, before being stimulated for 15 min with
PSS containing 0 or 100 nM CNP in the presence of 1 mM
IBMX. As shown (Fig. 4d), the presence of U0126 failed to
affect significantly the CNP-stimulated cGMP accumulation
(87.6 ± 8.8% cf. control response, P > 0.5). Collectively, these
data suggest that CNP-stimulated P-ERK1/2 is reliant on
MEK1/2 and Src kinase activity but is independent of Ca2+,
PKA, PKC or PI3K activity.
Biological consequence of CNP-stimulated P-ERK1/2
in GH3 cells
Having established that the effects of CNP on P-ERK1/2 were
independent of cGMP but dependent upon GC-B, we next
investigated the potential biological consequence of CNP-
stimulated P-ERK1/2. As ERK activity often regulates cell
proliferation, we examined the role of CNP on cell prolifera-
tion (by using cell counting, thymidine incorporation and met-
abolic activity assays) and cell cycle distribution (by using
flow cytometry). For each assay, GH3 cells were grown in
2% (v/v) FCS-containing media and treated with 0 or
100 nM CNP for 48 h, prior to being harvested. Cells grown
in normal medium (containing 10% [v/v] FCS) acted as a
positive control. In all cases, CNP failed to have an effect,
whereas the 10% serum-treated cells all demonstrated a sig-
nificantly increased cell number (by 160.3 ± 7.4%,
P < 0.0001; Fig. 5a), increased thymidine incorporation (to
126.8 ± 4.5%, P < 0.0001; Fig. 5b) or increased metabolic
activity (to 161.5 ± 5.1%, P < 0.0001; Fig. 5c). CNP also
failed to alter significantly the cell-cycle distribution
(Fig. 5d) in GH3 cells, although the presence of 10% (v/v)
FCS significantly enhanced S-phase and G2/M distribution
(to 62.9 ± 0.5% and 19.7 ± 0.5%, respectively; P < 0.0001),
while reducing G0/G1 phase distribution (to 17.4 ± 0.1%,
P < 0.0001).
Having excluded a proliferative effect of CNP in GH3
cells, we examined alternative biological consequences for
CNP-stimulated P-ERK1/2 in GH3 cells. As immunofluores-
cence microscopy had identified the nuclear localisation of P-
ERK1/2 in response to CNP (Fig. 2c–e’), we examinedwheth-
er CNP-stimulated P-ERK1/2 was needed for gene transcrip-
tion in GH3 cells, by examining the response of an ERK1/2-
sensitive promoter, the human glycoprotein hormone α-
subunit gene (αGSU), to CNP stimulation. GH3 cells were
transiently transfected with the human αGSU promoter and
stimulated for 8 h in the presence of CNP (0 to 1 μM). As
shown (Fig. 6a), CNP caused a concentration-dependent in-
crease in αGSU promoter activity (to 2.7 ± 0.2-fold and
3.3 ± 0.5-fold, P < 0.001 and P < 0.0001, for 100 nM and
1 μMCNP, respectively) but db-cGMP (1 mM) failed to have
any effect. In parallel experiments, transiently transfected
GH3 cells were pre-treated with the MEK inhibitor, U0126,
for 30 min prior to stimulation with CNP and throughout the
duration of the subsequent CNP stimulation. As shown
(Fig. 6b), U0126 caused a concentration-dependent inhibition
of CNP-stimulated αGSU promoter activity (to 60.7 ± 6.6%,
51.7 ± 10.3% and 43.7 ± 7.6%, P < 0.05, P < 0.001 and
P < 0.0001, for 3 μM, 10 μM and 30 μM U0126, respective-
ly). As P-ERK1/2 can target other transcriptional regulators
for phosphorylation, we examined the phosphorylation status
of p90-RSK, CREB, ATF1 and Elk-1 and the expression level
of endogenous MKP1 in GH3 cells stimulated with 100 nM
CNP. As shown (Fig. 6c), CNP treatment resulted in enhanced
phosphorylation of each of the transcriptional regulators, to-
gether with the elevated expression of MKP1, over the dura-
tion of the time-course. Furthermore, as many stimuli can
activate more than one member of the MAPK family, we
assessed the ability of CNP to enhance p38 MAPK and JNK
phosphorylation in GH3 cells. As shown (Supplemental
Fig. 2), CNP enhanced the phosphorylation and nuclear
localisation of both p38 MAPK and JNK in GH3 cells, an
effect that was mirrored in the murine pituitary LβT2 cell line
(Supplemental Fig. 3). These data suggest that gene transcrip-
tion and transcriptional regulators are the biological targets for
CNP-stimulated P-ERK1/2 in GH3 cells, rather than cell
proliferation.
Discussion
To date, biological effects mediated via the particulate
guanylyl cyclases appear to require cGMP generation (Potter
et al. 2006; Garbers et al. 2006). Despite the considerable
evidence for non-cGMP-dependent effects of natriuretic pep-
tides, these effects are mediated via the non-guanylyl cyclase,
NPR-C receptor (Anand-Srivastava 2005), or by a renal-
specific isoform (NPR-Bi) that fails to couple to cGMP
(Hirsch et al. 2003). In the current study, we provide evidence
Fig. 4 CNP-stimulated ERK1/2 phosphorylation requires MEK and
non-receptor tyrosine kinase activity. a GH3 cells were pre-treated for
30 min with various concentrations (0, 1, 3, 10, 30 μM) of U0126 (left)
or protein phosphatase 2 (PP2, right) before stimulation with CNP
(100 nM) for 15 min and subsequent Western blotting for phospho-
ERK1/2. b GH3 cells were pre-treated with 0 or 10 μM genistein,
herbimycin A, PP2 or PP3 for 30 min prior to stimulation with CNP
(100 nM) for 15 min and Western blotting for phospho-ERK1/2. Each
autoradiograph is representative of at least three independent experi-
ments. c Effect of mitogen-activated protein kinase phosphatase-1
(MKP1) over-expression on CNP-stimulated ERK1/2 phosphorylation.
GH3 cells were transiently reverse-transfected with 5 μg/well of either
pcDNA or MKP1 expression vector, prior to stimulation with CNP
(100 nM) for the indicated time point and subsequent Western blotting
for phospho-ERK1/2, MKP1 and β-Actin. d GH3 cells were pre-treated
for 30 min with 0 or 30 μM U0126, before being stimulated for 15 min
with PSS containing 0 or 100 nM CNP in the presence of 1 mM IBMX.
cGMP data are expressed as percentage of control response to CNP and
are means ± SEM from three independent determinations
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of a cGMP-independent GC-B-dependent signalling event ac-
tivated at concentrations lower than those required to initiate
guanylyl cyclase activity.
Many studies have demonstrated the anti-proliferative ef-
fects of natriuretic peptides in the endothelial, bone and neu-
ronal systems by mechanisms that predominantly involve the
activation of the guanylyl cyclase/cGMP/PKG pathways
(Chusho et al. 2001; Kaneki et al. 2008; Miyazawa et al.
2002; Krejci et al. 2005) or NPR-C activity (Gower et al.
2006). Our initial experiments reported here revealed the po-
tent stimulation of ERK1/2 phosphorylation.Whereas the cur-
rent observations were unexpected, given the previously re-
ported inhibitory effects of natriuretic peptides on MAPK sig-
nalling (Hagiwara et al. 1996; Kaneki et al. 2008), other stud-
ies have reported stimulatory effects of natriuretic peptides on
MAPK signalling in ventricular myocytes and in melanoma
cells (Silberbach et al. 1999; Dhayade et al. 2016). However,
these latter studies demonstrated a requirement for cGMP and
PKG in mediating the ANP and CNP effects on ERK1/2
phosphorylation (Silberbach et al. 1999; Dhayade et al.
2016), whereas our own findings suggest GC-B-mediated
ERK1/2 phosphorylation in GH3 cells is cGMP-independent.
Specifically, pharmacological cGMP analogues (db-cGMP)
failed to mimic the CNP effects on ERK1/2 phosphorylation
in GH3 cells and enhanced ERK1/2 phosphorylation occurred
at much lower concentrations of both CNP and ANP than are
required to stimulate cGMP accumulation in these cells.
Although we have not conclusively shown that cGMP signal-
ling is uninvolved in the ERK response, cGMP signalling
alone seems unlikely to be able to activate the ERK1/2 path-
way in GH3 cells.
The kinetics and compartmentalisation of phosphorylated
ERK1/2 can dictate the subsequent effects on downstream
signalling events (Cobb et al. 1994; Caunt et al. 2006). Here,
we show that CNP causes the enhanced phosphorylation of
ERK1/2-associated proteins (p90RSK, CREB, ATF-1 and
Elk-1). The enhanced phosphorylation of CREB, ATF-1 and
Elk-1 might contribute to the pronounced effect that CNP
elicits on the human αGSU promoter activity, which has been
shown to be MEK-dependent. We have previously observed a
robust response of the human αGSU promoter to CNP in
Fig. 5 CNP does not affect cell proliferation or cycle distribution in GH3
cells. In each case, GH3 cells were plated in 2% (v/v) FCS-containing
media and treated for 48 h with 0 or 100 nMCNP or with 10% (v/v) FCS
as a positive control, prior to being harvested for (a) cell counting, (b)
thymidine incorporation or (c) MTTassay. Data shown are means ± SEM
from three independent experiments, each performed in triplicate
(**P < 0.01, ****P < 0.0001, significantly different from Control). d
GH3 cells were plated in 2% (v/v) FCS-containing media and treated
for 48 h with 0 or 100 nM CNP or with 10% (v/v) FCS as a positive
control, prior to being harvested for flow cytometric analyses. Data
shown are means ± SEM from three independent experiments, each per-
formed in triplicate (****P < 0.0001, significantly different from each
phase of the cell cycle in Control cells)
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LβT2 cells but not αT3–1 cells (Thompson et al. 2009), sug-
gesting possible differences in the transcriptional regulation in
these gonadotroph-derived cell lines. Whether the transcrip-
tional response to CNP in LβT2 cells also requires MEK
activity, as our current findings demonstrate in GH3 cells,
remains to be determined. Furthermore, the concentration re-
sponses to CNP for cGMP accumulation, ERK1/2 phosphor-
ylation and αGSU promoter activity interestingly do not over-
lap (although these responses cannot be directly compared,
because of the differing sensitivities of each experimental ap-
proach) . However, the potent ia l combinat ion of
compartmentalised cGMP generation (for a review, see
Arora et al. 2013) together with the activation of MEK signal-
ling might contribute to shaping the biological responsiveness
to CNP. Such an interaction of cGMP and MEK pathways has
been previously demonstrated in osteoblasts (Rangaswami
et al. 2009). Finally, our findings that CNP also potently acti-
vates the JNK and p38 MAPK pathways in GH3 cells add
further complexity to GC-B down-stream signalling. Whereas
our data do not identify putative upstream kinases that might
explain this triple activation ofMAPK pathways in GH3 cells,
cross-activation of p38 MAPK and JNK might occur via
ERK1/2, as reviewed by others (Zhang and Liu 2002; Roux
and Blenis 2004; McKay and Morrison 2007).
Despite the prolonged nature of the ERK1/2 response to
CNP, GH3 cells failed to proliferate following a CNP chal-
lenge. In many other systems, CNP causes anti-proliferative
effects, predominantly via cGMP-dependent pathways
(Chusho et al. 2001; Kaneki et al. 2008; Miyazawa et al.
2002; Krejci et al. 2005). Although these effects are no doubt
cell-type-specific, dual activation of ERK1/2 phosphorylation
and cGMP production in GH3 cells might nullify any poten-
tial anti-proliferative effect of cGMP. However, whereas our
current investigations used a comprehensive range of cell pro-
liferation techniques, such data have to be interpreted with
caution when using tumour-derived cells lines, such as GH3
cells (Tashjian et al. 1968; Faivre-Bauman et al. 1975). The
potential effects of CNP on primary pituitary cell proliferation
and on ERK1/2 signalling remain to be elucidated.
Given the broad range of GC-A, GC-B and NPR-C expres-
sion, most cell types are likely to express at least one of these
mammalian natriuretic peptide receptors (Potter et al. 2006).
Non-cGMP-mediated effects of natriuretic peptides are usual-
ly attributed to NPR-C activity (Anand-Srivastava 2005);
however, our current studies failed to demonstrate a role for
NPR-C in GH3 cells. Limited reports have suggested that
splice variants and isoforms of the GC-B receptor exist in
mice and humans. At least three splice variants (GC-B1, 2
and 3) are expressed in mice, whereby GC-B1 and GC-B2
have guanylyl cyclase activity, although the partially truncated
GC-B2 is no longer hormone-sensitive (Tamura and Garbers
2003). GC-B3 is severely truncated and appears not to medi-
ate down-stream signalling events (Tamura and Garbers
2003). In human proximal tubules, the NprBi splice variant
regulates potassium channels in a non-cGMP- but tyrosine
kinase-dependent manner (Hirsch et al. 2003) as demonstrated
through genistein sensitivity. Importantly, CNP failed to
Fig. 6 CNP stimulates αGSU promoter activity in a MEK-dependent
manner. a GH3 cells were transiently transfected with 2.5 μg αGSU
promoter and stimulated with the indicated concentrations of CNP or
1 mM db-cGMP. Cells were harvested after 8 h and protein extracts
assayed for luciferase activity. Data shown are means ± SEM of three
independent experiments, each performed in triplicate and are expressed
as fold increase over basal. b GH3 cells transiently transfected with
αGSU promoter (as above) were pre-treated with the indicated concen-
tration of U0126 for 30 min prior to stimulation with CNP (100 nM).
Cells were harvested after 8 h and protein extracts assayed for luciferase
activity. Data shown are means ± SEM of three independent experiments,
each performed in triplicate and are expressed as fold increase over con-
trol response to CNP (*P < 0.1, ***P < 0.001, ****P < 0.0001; signif-
icantly different from control response, as determined by Bonferonni’s
multiple comparisons test). c CNP enhances phosphorylation of ERK1/2
pathway proteins. GH3 cells were stimulated with CNP (100 nM) for up
to 90 min, prior to extraction of total proteins andWestern blotting for the
indicated target proteins. Each autoradiograph is representative of at least
three independent experiments
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stimulate cGMP production via the NPR-Bi (Hirsch et al.
2003), whereas our current data show CNP to stimulate both
cGMP and ERK1/2 phosphorylation in GH3 cells.
Furthermore, we found that the rat GH3 cell line also ex-
presses all three splice variants described in mice and that
GC-B1 and GC-B2 are lost following siRNA targeting.
Therefore, one or both of these splice variants might mediate
the CNP effect on ERK1/2 signalling. However, the lack of
effect of numerous receptor-tyrosine kinase inhibitors (includ-
ing genistein), coupled to an intact cGMP response to CNP in
GH3 cells, suggests that a rat homologue of NprBi is not
involved.
GC-B signalling has been shown to be sensitive to
changes in intracellular calcium and PKC activity in many
cell types (Potter et al. 2006; Potter and Hunter 2000;
Abbey and Potter 2002; Abbey-Hosch et al. 2005).
Elevated calcium concentrations or enhanced PKC activity
have been shown to cause heterologous desensitisation of
GC-B-mediated cGMP accumulation (Potthast et al. 2004;
Fowkes et al. 2000; Thompson et al. 2014) and both of
these pathways mediate ERK1/2 activation in pituitary cell
lines (Mulvaney and Roberson 2000; Naor et al. 2000).
Our studies suggest that CNP-stimulated ERK1/2 phos-
phorylation does not require Ca2+ or PKC activity but does
need MEK1/2 activity and the partial activation of a non-
receptor tyrosine kinase (possibly Src kinase), as deter-
mined by PP2 treatments. Particulate guanylyl cyclase re-
ceptors are structurally similar to tyrosine kinase receptors;
the GC-B is not uncommon in this regard, itself harbouring
a tyrosine-kinase-like domain. Conventional receptor tyro-
sine kinases can activate the MAPK pathways via the Raf
and MEK pathways (McKay and Morrison 2007) but par-
ticulate guanylyl cyclases have not yet been demonstrated
to exert tyrosine kinase activity. In silico examination of
the intracellular domains of the GC-B receptor failed to
identify SH-2 domains and, thorough proteomic investiga-
tions of putative phosphorylation sites, did not identify
tyrosine residues (Potter and Hunter 1998). Thus, the exact
nature of the upstream participants that mediate GC-B-
dependent ERK1/2 phosphorylation remains enigmatic.
However, other studies have revealed the recruitment of
particulate guanylyl cyclases by the small GTPase pro-
teins, Rac and PAK (Guo et al. 2007). In their study,
PAK was shown to activate particulate guanylyl cyclases
directly in order to stimulate modest cGMP accumulation
(Guo et al. 2007) through a protein-protein interaction. Our
current data intriguingly juxtapose these findings and sug-
gest that a complimentary relationship exists between
growth factor receptor signalling and GC-B.
Particulate guanylyl cyclases are critical in mediating
a wide-range of homeostatic processes but these cannot
be explained solely by cGMP generation. Our work
suggests an intriguing additional mechanism by which
conventional GC-B receptors can signal, without the re-
quirement for cGMP and hints at novel biological roles
for these receptors in a range of tissues.
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